Apogee Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-14.0%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
-$4.75next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly1.3BTarget: Sufficient to fund operations into 2029 through planned BLA filing for zumilokibart in AD
Research and Development (R&D) Expenses Quarterly60.8MTarget: Reflects ongoing clinical trial progression and pipeline expansion
Net Loss Quarterly74.1MTarget: Expected to increase as late-stage clinical trials progress
Watch Items
- Zumilokibart (APG777) Phase 3 Trial Initiation in Atopic DermatitisTrigger: Initiation expected in the second half of 2026Action: Monitor regulatory alignment and first patient dosed milestones
- APG279 Phase 1b Head-to-Head Trial vs. DUPIXENTTrigger: Interim proof-of-concept data readout expected in 2H 2026Action: Evaluate comparative safety, PK/PD, and efficacy profiles
- Blackstone Life Sciences Strategic Financing TranchesTrigger: Completion of Phase 3 enrollment triggers next $100M trancheAction: Track enrollment progress and capital drawdowns
Research as of 2 Sep 2026